SYNTHETIC MODELS FOR HEMOCYANIN

血蓝蛋白的合成模型

• 批准号: 3152133
• 负责人: CHRISTOPHER A REED
• 金额: $ 9.31万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1982
• 资助国家: 美国
• 起止时间: 1982-04-01 至 1988-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3152133
• 关键词: X ray crystallography; antirheumatic agents; benzimidazoles; chelating agents; chemical models; chemical structure function; chemical synthesis; copper; hemocyanin; ligands; metalloproteins; orphan disease /drug; oxygen transport

It is proposed to apply the synthetic model approach to the oxygen-carying protein, hemocyanin, in order to gain an understanding of the fundamental active site chemistry. The synthetic chemistry involves the preparation of new benzimidazole chelating ligands which can hold copper ions in structures similar to those envisaged for the various states of hemocyanin. Having completed a detailed study of analogues of met-hemocyanin attention will now be focused on the more challenging problem of oxyhemocyanin. Emphasis will be placed on definitive characterization of crystalline materials by x-ray crystallography and spectroscopic methods (IR, ESR, UV-VIS, Resonance Raman). The compounds will provide well-defined systems on which to test the validity of recent electronic, vibrational and EXAFS spectroscopy applications to hemocyanin. The long term goal is to gain an understanding of the chemistry and biochemistry of copper proteins, particularly those having copper/dioxygen interactions. A detailed molecular level undertanding of copper proteins must underlie medical approaches to the therapy of disorders involving copper (e.g., Wilson's disease) or therapies using copper chelates (e.g., antiarthritic, antitumor agents).

提议将合成模型方法应用于含氧的方法 蛋白质，血阳蛋白，以了解基本 主动部位化学。 合成化学涉及准备 新的Benzimidazole螯合配体可以将铜离子固定在 类似于设想的各种状态的结构 血红蛋白。 完成了对类似物的详细研究 现在将关注大杂氨酸的注意力将集中在更具挑战性 羟蛋白酶的问题。 重点将放在确定性上 X射线晶体学和晶体材料的表征 光谱法（IR，ESR，UV-VIS，共振拉曼）。 化合物 将提供定义明确的系统，以测试最近的有效性 电子，振动和EXAFS光谱疗法应用到血氰蛋白酶。 长期目标是了解化学和 铜蛋白的生物化学，尤其是具有铜/二氧化物的生物化学 互动。 铜蛋白的详细分子水平进行 必须是涉及疾病治疗的医学方法 铜（例如，威尔逊氏病）或使用铜螯合物的疗法（例如， 抗性，抗肿瘤剂）。